First, magnets were placed in the receiver cell, and it was filled with 0.01 M PBS
Disclosures: Luca Fabris: Nothing to Disclose, Camilla Venturin: Nothing to Disclose, Yahima Frin-Herrera: Nothing to Disclose, Massimiliano Cadamuro: Nothing to Disclose, Claudia Mescoli: Nothing to Disclose, Umberto Cillo: Nothing to Disclose, Enrico Gringeri: Nothing to Disclose, Elena Campello: Nothing to Disclose, Mario Strazzabosco: Nothing to Disclose, Diego Calvisi: Nothing to Disclose, Antonio Cigliano: Nothing to Disclose, Paolo Simioni: Nothing to Disclose 1938 TRANSPOSON-BASED ONCOGENES INTEGRATION IN ABCB4 (MDR2)-/- MICE RECAPITULATES HIGH SUSCEPTIBILITY TO CHOLANGIOCARCINOMA IN PRIMARY SCLEROSING CHOLANGITIS Pinzhu Huang 1 Guangyan Wei 1 Jesse Kirkpatrick 2 MARAM ALENZI 1 Yi Lin 1 Li Tan 1 Disha Badlani 1 Li Chen 3 Mathieu Petitijean 3 Kahini Vaid 1 Shuangshuang Zhao 1 Alicia lugovskoy 1 Xin Chen 4 Gregory Gores 4 Yury Popov 1 , 1 Division of Gastroenterology and Hepatology, BIDMC, Harvard Medical School, 2 Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, 3 PharmaNest, Inc, NJ, 4 Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN Background: Cholangiocarcinoma (CCA) is a dreaded complication of primary sclerosing cholangitis (PSC), difficult to diagnose and associated with high mortality
These findings have expanded ipamorelin's research relevance into gastrointestinal biology beyond its primary GH secretagogue profile
didemnin B
TNF- antagonists, such as infliximab, have emerged as promising options due to their ability to mitigate the neuroinflammatory processes that contribute to RGC apoptosis and optic nerve degeneration
